Kim, H. (2015). Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters. International Journal of Health Policy and Management, 4(12), 813-821. doi: 10.15171/ijhpm.2015.157
Hyosun Kim. "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters". International Journal of Health Policy and Management, 4, 12, 2015, 813-821. doi: 10.15171/ijhpm.2015.157
Kim, H. (2015). 'Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters', International Journal of Health Policy and Management, 4(12), pp. 813-821. doi: 10.15171/ijhpm.2015.157
Kim, H. Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters. International Journal of Health Policy and Management, 2015; 4(12): 813-821. doi: 10.15171/ijhpm.2015.157
Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters
School of Media and Journalism, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
Abstract
Background For the purpose of understanding the Food and Drug Administration’s (FDA’s) concerns regarding online promotion of prescription drugs advertised directly to consumers, this study examines notices of violations (NOVs) and warning letters issued by the FDA to pharmaceutical manufacturers.
Methods The FDA’s warning letters and NOVs, which were issued to pharmaceutical companies over a 10-year period (2005 to 2014) regarding online promotional activities, were content-analyzed.
Results Six violation categories were identified: risk information, efficacy information, indication information, product labeling, material information issues, and approval issues. The results reveal that approximately 95% of the alleged violations were found on branded drug websites, in online paid advertisements, and in online videos. Of the total 179 violations, the majority of the alleged violations were concerned with the lack of risk information and/or misrepresentation of efficacy information, suggesting that achieving a fair balance of benefit versus risk information is a major problem with regard to the direct-to-consumer advertising (DTCA) of prescription drugs. In addition, the character space limitations of online platforms, eg, sponsored links on search engines, pose challenges for pharmaceutical marketers with regard to adequately communicating important drug information, such as indication information, risk information, and product labeling.
Conclusion Presenting drug information in a fair and balanced manner remains a major problem. Industry guidance should consider addressing visibility and accessibility of information in the web environment to help pharmaceutical marketers meet the requirements for direct-to-consumer promotion and to protect consumers from misleading drug information. Promotion via social media warrants further attention, as pharmaceutical manufacturers have already begun actively establishing a social media presence, and the FDA has thus begun to keep tabs on social media promotions of prescription drugs.
Highlights
Commentaries Published on this Paper
The Conundrum of Online Prescription Drug Promotion; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
Still the Great Debate – “Fair Balance” in Direct-to-Consumer Prescription Drug Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
The Tip of the Iceberg of Misleading Online Advertising; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
Digital Direct-to-Consumer Advertising: A Perfect Storm of Rapid Evolution and Stagnant Regulation; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: Teaching Drug Marketers How to Inform Better or Spin Better?; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
Future Challenges and Opportunities in Online Prescription Drug Promotion Research; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
Considering the Future of Pharmaceutical Promotions in Social Media; Comment on “Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters”
Dobrow L. DTC Report: DTC Gets Smart - Medical Marketing and Media. Med Mark Media. http://www.mmm-online.com/features/dtc-report-dtc-gets-smart/article/339357/. Accessed August 22, 2015. Published 2014.
Lorence D, Churchill R. A study of the web as DTC drug marketing agent. J Med Syst. 2007;31(6):551-556. doi:10.1007/s10916-007-9098-4
Liang BA, Mackey TK. Prevalence and global health implications of social media in direct-to-consumer drug advertising. J Med Internet Res. 2011;13(3):e64.
Schwartz V, Silverman C, Hulka M, Appel C. Marketing pharmaceutical products in the twenty-first century: an analysis of the continued viability of traditional principles of law in the age of direct-to-consumer advertising. Harv J Law Public Policy. 2009;32:333-354.
Bell R, Kravitz R, Wilkes M. Direct-to-consumer prescription drug advertising and the public. J Gen Intern Med. 1999;14(11):651-657.
Sheehan K. Balancing acts: an analysis of Food and Drug Administration letters about direct-to-consumer advertising violations. J Public Policy Mark. 2003;22(2):159-169.
Vogt DU. CRS Report for Congress: Direct-to-Consumer Advertising of Prescription Drugs. Congressional Research Service; 2005.
Welch Cline RJ, Young HN. Marketing drugs, marketing health care relationships: a content analysis of visual cues in direct-to-consumer prescription drug advertising. Health Commun. 2004;16(2):131-157.
Lurie P. DTC advertising harms patients and should be tightly regulated. J Law Med Ethics. 2009;37(3):444-450. doi:10.1111/j.1748-720X.2009.00405.x
Gibson S. Regulating direct-to-consumer advertising of prescription drugs in the digital age. Laws. 2014;3(3):410-438.
Sheehan K. Direct-to-consumer (DTC) branded drug web sites risk presentation and implications for public policy. J Advert. 2007;36(3):123-135. doi: 10.2753/JOA0091-3367360310
Huh J, Cude B. Is the information “fair and balanced” in direct-to-consumer prescription drug websites? J Health Commun. 2004;9(6):529-540.
Liang BA, Mackey T. Direct-to-consumer advertising with interactive internet media: global regulation and public health issues. J Am Med Assoc. 2011;305(8):824-825. doi:10.1001/jama.2011.203
Kreuter M, Bull F, Clark E, Oswald D. Understanding how people process health information: a comparison of tailored and nontailored weight-loss materials. Heal Psychol. 1999;18(5):487-494.
Bettman J, Kakkar P. Effects of information presentation format on consumer information acquisition strategies. J Consum Res. 1977;3(4):233-240.
Yoo CY, Kim K, Stout PA. Assessing the effects of animation in online banner advertising: hierarchy of effects model. J Interact Advert. 2004;4(2):49-60.
Sewak S, Wilkin N, Bentley J, Smith M. Direct-to-consumer advertising via the Internet: The role of Web site design. Res Social Adm Pharm. 2005;1(2):289-309. doi:10.1016/j.sapharm.2005.03.012